| View |
|
BR-1000
|
Japanese Encephalitis Virus (Live, Attenuated)
|
Imojev
|
Formulation: After reconstitution, one dose (0.5 mL) contains 4.0-5.8 log Plaque Forming Units (PFU) live, attenuated, recombinant Japanese Encephalitis Virus.
|
Powder for Suspension for Injection (SC)
|
-
|
Government Pharmaceutical Organization - Merieux Biological Products Co., Ltd.
|
Thailand
|
Initial (Variation)
|
13 July 2022
|
13 July 2027
|
| View |
BR-1004_PI_01.pdf
|
BR-1004
|
Heparin Sodium
|
Heparin Leo
|
1,000 IU/mL
|
Solution For Injection (IV/SC)
|
Anticoagulant
|
Leo Pharma A/S
|
Denmark
|
Automatic Renewal (Variation)
|
09 March 2023
|
09 March 2028
|
| View |
BR-1005_PI_01.pdf
|
BR-1005
|
Heparin Sodium
|
Heparin Leo
|
5,000 IU/mL
|
Solution For Injection (IV/SC)
|
Antithrombotic Agents
|
Leo Pharma A/S
|
Denmark
|
Initial (Variation)
|
23 March 2023
|
23 March 2028
|
| View |
|
BR-1008
|
Human Insulin (rDNA)
|
Actrapid
|
100 IU/mL
|
Solution For Injection (Im/Iv/Sc)
|
Antidiabetic
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
05 April 2024
|
06 May 2029
|
| View |
|
BR-1009
|
Insulin Human
|
Insulatard Flexpen
|
100 U/mL
|
Suspension For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Regular Renewal
|
08 March 2021
|
13 August 2025
|
| View |
|
BR-1010
|
Isophane Insulin Human, Recombinant DNA
|
Insulatard
|
100 IU/mL
|
Suspension For Injection
|
Intermediate-acting Insulin
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
02 August 2023
|
20 August 2028
|
| View |
|
BR-1011
|
Insulin Detemir
|
Levemir FlexPen
|
100 U/ mL
|
Solution for injection
|
Antidiabetic
|
Novo Nordisk A/S
|
Denmark
|
Automatic Renewal
|
03 February 2022
|
22 December 2026
|
| View |
|
BR-1012
|
Insulin Human
|
Mixtard 30 FlexPen
|
100 IU/mL (Soluble Insulin 30% and Isophane Insulin 70%)
|
Suspension For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
-
|
08 March 2021
|
25 August 2025
|
| View |
|
BR-1013
|
Somatropin
|
Norditropin SimpleXx
|
5 mg / 1.5 mL
|
Solution For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
-
|
19 April 2021
|
15 November 2025
|
| View |
|
BR-1014
|
Biphasic Insulin Aspart 30
|
NovoMix 30 FlexPen
|
100 IU/ mL
|
Suspension for injection (SC)
|
Antidiabetic
|
Novo Nordisk A/S
|
Denmark
|
Automatic Renewal
|
01 February 2022
|
21 December 2026
|
| View |
|
BR-1015
|
Insulin Aspart
|
NovoRapid Flexpen
|
100 IU/ mL
|
Solution For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
-
|
08 March 2021
|
13 August 2025
|
| View |
|
BR-1016
|
Liraglutide
|
Victoza
|
6mg/mL
|
Solution For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
-
|
26 November 2021
|
07 February 2026
|
| View |
|
BR-1018
|
Darbepoetin Alfa
|
Nesp
|
20mcg/0.5mL
|
Solution For Injection (I.V. / S.C.)
|
-
|
Terumo Corporation (Kofu Factory)
|
Japan
|
Initial
|
09 October 2020
|
26 January 2025
|
| View |
|
BR-1019
|
Darbepoetin Alfa
|
Nesp
|
30mcg/0.5mL
|
Solution For Injection (I.V. / S.C.)
|
-
|
Terumo Corporation (Kofu Factory)
|
Japan
|
Initial
|
09 October 2020
|
26 January 2025
|
| View |
|
BR-1020
|
Darbepoetin Alfa
|
Nesp
|
40mcg/0.5mL
|
Solution For Injection (I.V./S.C.)
|
-
|
Terumo Corporation (Kofu Factory)
|
Japan
|
Initial
|
09 October 2020
|
26 January 2025
|
| View |
|
BR-1026
|
Laronidase
|
Aldurazyme
|
580 mcg/mL (2.9 mg/5 mL)
|
Concentrated Solution for IV Infusion
|
-
|
Biomarin Pharmaceutical Inc.
|
U.S.A
|
-
|
22 March 2022
|
29 September 2026
|
| View |
|
BR-1046
|
Insulin Glulisine
|
Apidra
|
3.49 mg/mL (equivalent to 100 Units/mL)
|
Solution for Subcutaneous/Continuous SC Pump Infusion/
Intravenous Injection
|
-
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
-
|
26 February 2021
|
28 October 2025
|
| View |
BR-1047_PI_01.pdf
|
BR-1047
|
Agalsidase Beta
|
Fabrazyme
|
5 mg
|
Powder for Concentrate for Solution for Infusion (IV)
|
Enzyme
|
Genzyme Ireland Limited
|
Ireland
|
Initial (from Monitored Release)
|
13 September 2024
|
13 September 2029
|
| View |
|
BR-1048
|
Agalsidase Beta
|
Fabrazyme
|
35 mg
|
Powder for Concentrate for Solution for
Infusion (IV)
|
-
|
Genzyme Ireland Limited
|
Ireland
|
Renewal
|
21 November 2023
|
07 December 2028
|
| View |
|
BR-1053
|
Insulin Lispro (rDNA origin)
|
Humalog Kwikpen
|
100 units/mL
|
Solution for Injection (IM/IV/SC)
|
-
|
Eli Lilly Italia S.p.A.
|
Italy
|
Initial (Variation)
|
25 October 2022
|
25 October 2027
|